Delhi HC allows Zydus Lifesciences to sell breast cancer drug Sigrima

The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being similar to Roche's Perjeta. The court invalidated an earlier restraint order, noting no patent infringement by Zydus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTvDiMN
via IFTTT